Objective : The effects of miglitol on postprandial glucose and lipid metabolism were investigated in patients with type 2 diabetes mellitus T2DM treated with diet alone. Subjects and Methods : A meal tolerance test MTT was performed in 26 diabetic patients before and 2 weeks after 150 mg / day miglitol treatment, with the second MTT performed in patients after they had taken a dose of 50 mg miglitol. Results : Miglitol treatment decreased postprandial blood glucose and serum insulin levels 30 and 60 min after meal loading, but there was no change in blood glucose levels at 120 min. In addition, there were no significant decreases in the area under the curve AUC of blood glucose and serum insulin levels. However, the AUC of postprandial serum triglycerides and incremental triglycerides decreased signi cantly, as did the AUC of postprandial incremental remnant-like particle cholesterol. There were no signi cant changes in total cholesterol, high-density lipoprotein-cholesterol and low-density lipoprotein-cholesterol. Conclusions : Miglitol treatment improves postprandial hyperlipidemia, as well as postprandial hyperglycemia, in patients with T2DM. In T2DM patients treated with -glucosidase inhibitors alone, measuring blood glucose levels 120 min after a meal may not be the best way to monitor postprandial glucose metabolism.
of myocardial infarction [7] [8] [9] [10] [11] . Postprandial hyperlipidemia is often associated with elevated plasma levels of the remnant lipoprotein fraction, the appearance of small, dense low-density lipoprotein LDL , and a decrease in high-density lipoprotein-cholesterol HDL-C . The postprandial state characterized by abnormally increased glucose and lipid levels has been referred to as postprandial dysmetabolism 12 .
-Glucosidase inhibitors have been reported to treat postprandial hyperglycemia and hypertension, as well as to suppress the incidence of cardiovascular events 13 . In a previous study we showed that acarbose, an -glucosidase inhibitor, suppresses plasma levels of the remnant fraction in the fasting state 14 . Thus, the aim of the present study was to determine whether miglitol, one of the new -glucosidase inhibitors 15, 16 , can improve postprandial hyperglycemia and hyperlipidemia simultaneously in patients with type 2 diabetes mellitus T2DM treated by diet alone. To assess postprandial glucose and lipid metabolism simultaneously we used Test meal A , which was designed by the Japan Diabetes Society Test Meal Development Working Group 17 .
Methods

Study subjects
Twenty-six T2DM patients treated with diet alone and without a history of cardiovascular complications, hepatic disorders, thyroidal dysfunction, and renal failure were enrolled in the present study. None of the patients had taken any hypoglycemic or antihyperlipidemic agents, or had had insulin injections. All of the diabetic patients were Japanese and all were outpatients of Toho University Omori Medical Center and Makita General Hospital. In addition, six non-diabetic healthy volunteers were enrolled in the study. All subjects provided written informed consent prior to participating in the study. None of the subjects received any compensation for participating in the study. The baseline characteristics of the subjects are given in Kagaku Kenkyusho, Tokyo, Japan , to be taken before each meal, three times a day, for 2 weeks. The second meal tolerance test was performed with only diabetic patients in the same manner, with taking 50 mg miglitol before consuming the test meal Fig. 1 .
Biochemical measurements
In the present study, HbA1c values were estimated as Japan Diabetes Society JDS equivalent values calculated using the formula HbA1c HbA1c National Glycohemoglobin Standardization Program NGSP 0.4 , based on previous determinations of the relationship between HbA1c JDS , as measured by Japanese standard substance and measurement methods, and HbA1c NGSP 18 . Blood glucose levels were measured using the glucose-oxidase method, whereas serum insulin levels were determined as the Chemiluminescent Immuno Assay CLIA . Serum lipid levels were measured using an autoanalyzer and serum remnant-like particle cholesterol RLP-C levels were determined using an immunoaf nity column 19 .
Statistical analysis
Data were checked for normal distribution. Data during the meal tests were analyzed by repeated-measures analysis of variance ANOVA . Data were also analyzed using Steel s multiple comparison test for multiple related samples. All analyses were performed using SPSS software package IBM Corp. , and significance was set at 0.05. In case of correspondence, data were analyzed using Student s t-test and paired t-test. The area under the curve AUC was estimated by calculating the sum of the area between each sampling point. Comparisons of AUCs were made using paired t-tests.
Results
The most common adverse gastrointestinal tract events associated with -glucosidase inhibitors are flatulence, diarrhea, and abdominal pain. In the present study, all diabetic patients tolerated miglitol well and no adverse events were observed.
Blood glucose levels of diabetic patients were signi cantly higher at every sampling point than those in healthy volunteers, with a peak at 60 min after the test meal in T2DM patients Fig. 2a . Serum insulin peaked at 90 min after the test meal in diabetic patients, compared with a peak at 30 min in healthy volunteers Fig. 2b .
After miglitol treatment, fasting blood glucose level did not change, but the peak in postprandial blood glucose levels shifted from 60 to 90 min, but did not change at all at 120 min. In addition, miglitol treatment significantly decreased postprandial blood glucose levels P 0.01, repeated-measures ANOVA ; Fig. 2a After miglitol treatment, there was a tendency for postprandial serum triglyceride and incremental triglyceride to decrease, but the differences were not significant P 0.05, Table 2 . Miglitol treatment had no effect on postprandial levels of total cholesterol, HDL-C, and LDL-C.
Discussion
To assess postprandial glucose and lipid metabolism simultaneously, we used the JANEF F48 meal Kewpie , which was produced according to the formula of Test Meal A . To characterize glucose and lipid excursions after test meal loading in diabetic patients, we also performed test meal loading in non-diabetic healthy subjects. Blood glucose levels of diabetic patients at every sampling point were signi cantly higher than those in the healthy volunteers, with the peak shifted from 30 to 60 min. The serum insulin peak was shifted in diabetic patients from 30 to 90 min. Thus, this test meal loading is suitable for the investigation of blood glucose and insulin responses in patients with mild diabetes.
In diabetic patients, possibly because of a suppressed blood glucose response caused by miglitol, postprandial serum insulin levels decreased significantly Fig. 2b . Thus, miglitol treatment may have favorable effects in diabetic patients from the viewpoint of insulin resistance. In support of this, average HOMA-R decreased to below 2.5, which is the lower All data are expressed as the mean SD. The number in parenthesis indicates the subject number. Signi cant differences between before and after treatment in diabetic subjects are indicated by p values paired t-test was employed . Miglitol on postprandial metabolism limit for the presence of insulin resistance according to the recommendations of the Japanese Diabetes Society 20 .
Miglitol treatment shifted the peak of postprandial blood glucose levels from 60 to 90 min in diabetic patients Fig. 2a . However, as indicated in Table 2 , miglitol did not decrease the AUC of blood glucose 0-3 h . It has been suggested that the effect of miglitol is only to delay carbohydrate absorption 21 . Most of the carbohydrates in the small intestine may be digested within 3 h, despite miglitol treatment.
In diabetic patients, the peak of postprandial glucose shifted from 60 to 90 min after meal, whereas levels at 120 min did not change at all after miglitol treatment Fig. 2a .
The International Diabetes Federation IDF Guidelines for the Management of Postmeal Glucose 22 recommend monitoring 2-h postprandial glucose levels for the prevention of cardiovascular events. However, it may be inappropriate to monitor 2-h glucose levels during treatment with -glucosidase inhibitors alone because of a shift in the timing of the blood glucose peak. On the basis of the results of the present study, we recommend monitoring 1-h postprandial glucose levels during treatment with -glucosidase inhibitors.
Although it is known that 2-h postprandial hyperglycemia is related to chronic complications of diabetes and is currently used in international guidelines to drive therapy 22 , Esposito et al have reported that incremental glucose peaks IGP in the everyday life of patients with T2DM occur for most patients 95 within 1 h after a meal 23 . Furthermore, they suggested that there is a good correlation between IGP and carotid intima-media thickness, and that the timing of the IGP is not in uenced by treatment diet or drugs . These ndings support our proposal to monitor 1-h post-meal glucose levels.
After miglitol treatment, the AUC of serum triglycerides decreased signi cantly in diabetic subjects Table 2 . It is possible that slowing of monosaccharide absorption by miglitol may result in the suppression of triglyceride production in the small intestine. In diabetic patients, serum RLP-C levels after test meal loading did not change with miglitol treatment Fig. 2d . However, if we estimate the incremental RLP-C from Time 0, the RLP-C increment was suppressed at 30, 60, 90, and 120 min following treatment Fig. 2f . It is of interest that miglitol suppressed the post-meal RLP-C levels in diabetic patients. Because a single dose of acarbose, another -glucosidase inhibitor, cannot suppress postprandial triglyceride levels in diabetic patients 24 and insulin-resistant states are known to induce overproduction of chylomicron from the small intestine 25 , it is speculated that improvement of the insulin resistant state following 2 weeks treatment with miglitol may result in suppression of post-meal increases in RLP-C levels.
The postprandial state characterized by abnormally increased levels of glucose and lipids also referred to as postprandial dysmetabolism is now proposed to be an independent predictor of future cardiovascular events 12 . Yokoyama et al reported that miglitol treatment increased adiponectin levels and decreased the urinary albumin excretion rate in T2DM patients 26 . Suppression of the postprandial glucose spike may protect diabetic patients against the development of early stage renal damage and may also increase adiponectin secretion from adipocytes. These possibilities warrant further investigation.
Large swings in glucose concentrations in the culture medium of human umbilical vein cells have been reported to stimulate cell apoptosis 27 . Furthermore, Mita et al reported that the area of the arteriosclerotic lesion in ApoE-deficient mice decreased after miglitol treatment 28 . It is possible that in ApoE-de cient mice miglitol treatment minimized the glucose swing, thereby decreasing the area of arteriosclerotic lesions.
In conclusion, miglitol treatment improved not only postprandial glucose, but also triglyceride and remnant lipoprotein metabolism in T2DM patients who were not able to optimize glucose control by diet alone. The findings of the present study suggest that miglitol may have a bene cial effect in preventing atherogenesis in T2DM by improving postprandial dysmetabolism. Furthermore, it is of noteworthy that monitoring 2-h post-meal glucose levels is not suitable in diabetic patients being treated with -glucosidase inhibitors alone. In these patients, it is recommended that 1-h post-meal glucose levels are monitored instead of 2-h levels.
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